Access
To read this story in full you will need to login or make a payment (see right).
Commentary
Nature Medicine 10, 769 - 771 (2004)
doi:10.1038/nm0804-769
Urgently needed: a filter for the HIV-1 vaccine pipeline
John P Moore1 & Dennis R Burton2
- John P. Moore is in the Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA. e-mail: jpm2003@med.cornell.edu
- Dennis R. Burton is in the Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California, USA. e-mail: burton@scripps.edu
Abstract
Research groups worldwide are trying to make immunogens intended to elicit neutralizing antibody responses as part of a prophylactic vaccine to counter the spread of HIV-1. The relative merits of different designs can only be gauged properly through comparative studies, and particularly by evaluating human or animal antisera under identical, or comparable, conditions. Hence there is a need for assay standardization and for the creation of a centralized testing facility that could distribute consensus protocols and reagents.
There is widespread acceptance that the induction of virus-neutralizing antibodies (NAbs) will be crucial to any truly effective vaccine against human immunodeficiency virus type 1 (HIV-1)1, 2, 3. The most likely design of such a vaccine will include both a component to elicit cellular immunity (particularly effector cytotoxic T lymphocytes (CTLs)) and one to stimulate the humoral immune system, especially NAbs.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
HIV?1 neutralizing antibodies: How full is the bottle?Nature Medicine News and Views (01 Feb 1999)
Neutralizing antibodies take a swipe at HIV in vivoNature Medicine News and Views (01 Jun 2005)
See all 4 matches for News And Views